



Correction for Oh et al., “Development of a Broth Microdilution Method for Exebacase Susceptibility Testing”

Jun T. Oh,^a Jane E. Ambler,^a Cara Cassino,^a  Raymond Schuch^a

^aContraFect Corporation, Yonkers, New York, USA

Volume 65, no. 7, e02587-20, 2021, <https://doi.org/10.1128/AAC.02587-20>. In Table 4, a single methicillin-susceptible *Staphylococcus aureus* isolate inhibited by 0.12 $\mu\text{g/ml}$ of exebacase is presented, and the remaining 148 isolates tested have an exebacase MIC range of 0.25 to 1 $\mu\text{g/ml}$. Further investigation of the isolate with an exebacase MIC of 0.12 $\mu\text{g/ml}$ to confirm bacterial identification (by MALDI-TOF) and MIC revealed the isolate to be *Staphylococcus pseudintermedius*. Based on this finding, the authors wish to correct Table 4 and the corresponding text that refers to the *S. aureus* MIC data accordingly. With these corrections, the interpretation and conclusions of the article remain the same.

There are four instances in the article denoting the total number of *S. aureus* isolates as 149; this should be corrected to 148 isolates, as follows: (1) last paragraph of the introductory section, “. . .MIC distribution generated by testing 149 *S. aureus* clinical isolates. . .” should read “. . .MIC distribution generated by testing 148 *S. aureus* clinical isolates. . .”; (2) in the Results section, the paragraph header “Exebacase *in vitro* activity against 149 clinical *S. aureus* isolates” should read “Exebacase *in vitro* activity against 148 clinical *S. aureus* isolates”; (3) in Table 4, the *n* value for the total number of *S. aureus* isolates tested should be 148; and (4) in the first paragraph of Materials and Methods, “The collection of 149 clinical *S. aureus* isolates. . .” should read “The collection of 148 clinical *S. aureus* isolates. . .”

There are three instances in the article denoting 74 MSSA; this should be changed to 73 MSSA, as follows: (1) in the Results section, in the paragraph “Exebacase *in vitro* activity against 148 clinical *S. aureus* isolates,” “74 MSSA” should read “73 MSSA”; (2) in Table 4, the *n* value for MSSA isolates tested should be 73; and (3) in the first paragraph of Materials and Methods, “74 MSSA” should read “73 MSSA.”

Table 4 should appear as shown below.

TABLE 4 Exebacase MICs determined in CAMHB-HSD using frozen-form panels

Organism	<i>n</i>	No. with exebacase MIC ($\mu\text{g/ml}$) ^a			MIC ($\mu\text{g/ml}$)		Range
		0.25	0.5	1	50%	90%	
<i>S. aureus</i>	148	5	124	19	0.5	1	0.25–1
MSSA	73	4	62	7	0.5	0.5	0.25–1
MRSA	75	1	62	12	0.5	1	0.25–1

^aNo isolates had MICs of 0.12 or 2 $\mu\text{g/ml}$.

Citation Oh JT, Ambler JE, Cassino C, Schuch R. 2021. Correction for Oh et al., “Development of a broth microdilution method for exebacase susceptibility testing.” *Antimicrob Agents Chemother* 65:e01658-21. <https://doi.org/10.1128/AAC.01658-21>.

Copyright © 2021 American Society for Microbiology. All Rights Reserved.

Address correspondence to Raymond Schuch, rschuch@contrafect.com.

Published 17 September 2021